✦ LIBER ✦

Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors

✍ Scribed by Carlos Castaneda; Kellen L. Meadows; Roxanne Truax; Michael A. Morse; Scott H. Kaufmann; William P. Petros; Yali Zhu; Paul Statkevich; David L. Cutler; Herbert I. Hurwitz

Publisher: Springer
Year: 2010
Tongue: English
Weight: 358 KB
Volume: 67
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-010-1488-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I safety, pharmacological, and b

A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors

✍ Laura Q. M. Chow; S. Gail Eckhardt; Cindy L. O’Bryant; Mary Kay Schultz; Mark Mo 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 697 KB

Phase I study of TZT-1027, a novel synth

Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses

✍ Kenji Tamura; Kazuhiko Nakagawa; Takayasu Kurata; Taroh Satoh; Toshiji Nogami; K 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 342 KB

A phase I, open-label, randomized crosso

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors

✍ Suzanne Leijen; Patricia M. M. B. Soetekouw; T. R. Jeffry Evans; Marianne Nicols 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 303 KB